Postacute Sequelae of COVID-19 in Pediatric Patients Within the United States: A Scoping Review.

Christine M Miller, Carla Borre, Alex Green, Melissa Funaro, Carlos R Oliveira, Akiko Iwasaki
Author Information
  1. Christine M Miller: Department of Pediatrics, Division of Infectious Diseases and Global Health, Yale University School of Medicine New Haven, New Haven, CT.
  2. Carla Borre: Department of Pediatrics, Division of Infectious Diseases and Global Health, Yale University School of Medicine New Haven, New Haven, CT.
  3. Alex Green: Department of Pediatrics, Division of Infectious Diseases and Global Health, Yale University School of Medicine New Haven, New Haven, CT.
  4. Melissa Funaro: Harvey Cushing/John Hay Whitney Medical Library, Yale University, New Haven, CT.
  5. Carlos R Oliveira: Department of Pediatrics, Division of Infectious Diseases and Global Health, Yale University School of Medicine New Haven, New Haven, CT.
  6. Akiko Iwasaki: Department of Immunobiology, Yale School of Medicine, New Haven, CT.

Abstract

A subset of children and adolescents experience recurrent or persistent symptoms following SARS-CoV-2 infection, known as postacute sequelae of COVID-19 (PASC), however, the clinical epidemiology within the United States (US) is not yet well understood. This scoping review aims to synthesize the clinical epidemiology of pediatric PASC in the US. A comprehensive literature search was conducted and databases were queried from inception until January 29, 2024. Studies including US children and adolescents <21 years old were considered. From 1028 studies identified, 29 met the inclusion criteria. Prevalence of PASC ranged from less than 1%-27%. Risk factors included older age, female sex, asthma, obesity, and severe initial infection. Common symptoms were dyspnea, fatigue, headaches, and chest pain. A multidisciplinary approach for diagnosis and management was common across studies. Most studies had a high risk of bias and were limited by a lack of standardized definitions and short follow-up duration. This review establishes a foundation for understanding pediatric PASC and highlights the critical need for continued research to optimize prevention and treatment strategies.

Keywords

References

  1. BMJ. 2021 Mar 29;372:n71 [PMID: 33782057]
  2. J Infect. 2024 Feb;88(2):77-88 [PMID: 38101521]
  3. PLoS One. 2023 Dec 28;18(12):e0293600 [PMID: 38153928]
  4. Nature. 2023 Nov;623(7985):139-148 [PMID: 37748514]
  5. Viruses. 2023 Feb 20;15(2): [PMID: 36851793]
  6. Ann Intern Med. 2013 Feb 19;158(4):280-6 [PMID: 23420236]
  7. Pediatr Pulmonol. 2022 Oct;57(10):2455-2463 [PMID: 35775163]
  8. Neurol Sci. 2021 Oct;42(10):3959-3963 [PMID: 34247285]
  9. Healthcare (Basel). 2022 Nov 30;10(12): [PMID: 36553942]
  10. Pediatr Int. 2022 Jan;64(1):e15177 [PMID: 35522823]
  11. J Am Board Fam Med. 2022 May-Jun;35(3):570-578 [PMID: 35641057]
  12. Nat Immunol. 2024 Feb;25(2):218-225 [PMID: 38212464]
  13. Prim Care Companion CNS Disord. 2022 Apr 26;24(2): [PMID: 35486940]
  14. Eur J Pediatr. 2022 Apr;181(4):1597-1607 [PMID: 35000003]
  15. Eur Respir J. 2024 Mar 14;63(3): [PMID: 38359962]
  16. Can Med Assoc J. 1931 Jun;24(6):828-30 [PMID: 20318336]
  17. J Am Coll Health. 2023 Jul;71(5):1367-1373 [PMID: 34242539]
  18. Acta Paediatr. 2023 Jun;112(6):1284-1286 [PMID: 36938946]
  19. BMJ. 2023 Jan 11;380:e072529 [PMID: 36631153]
  20. Int J Environ Res Public Health. 2022 Oct 17;19(20): [PMID: 36293968]
  21. Am J Phys Med Rehabil. 2021 Dec 1;100(12):1140-1147 [PMID: 34793374]
  22. JAMA Pediatr. 2022 Oct 1;176(10):1000-1009 [PMID: 35994282]
  23. Clin Microbiol Infect. 2022 Apr;28(4):611.e9-611.e16 [PMID: 34763058]
  24. J Clin Epidemiol. 2016 Jul;75:40-6 [PMID: 27005575]
  25. J Clin Med. 2022 Nov 16;11(22): [PMID: 36431250]
  26. JAMA Netw Open. 2023 Dec 1;6(12):e2349613 [PMID: 38153737]
  27. EClinicalMedicine. 2023 May;59:101961 [PMID: 37073325]
  28. Muscle Nerve. 2005 Jan;31(1):6-19 [PMID: 15599928]
  29. Pediatrics. 2024 Apr 1;153(4): [PMID: 38225804]
  30. Pediatr Res. 2024 Jul;96(2):319-324 [PMID: 38287106]
  31. Pediatr Pulmonol. 2021 Dec;56(12):3682-3687 [PMID: 34534416]
  32. J Pediatric Infect Dis Soc. 2023 Feb 27;12(2):113-116 [PMID: 36548966]
  33. J Child Neurol. 2022 Apr;37(5):426-433 [PMID: 35072534]
  34. Neurocrit Care. 2021 Oct;35(2):283-290 [PMID: 34184177]
  35. Pediatr Infect Dis J. 2024 Aug 1;43(8):795-802 [PMID: 38713816]
  36. Nat Med. 2022 May;28(5):911-923 [PMID: 35585196]
  37. Clin Pediatr (Phila). 2022 Feb;61(2):188-193 [PMID: 34859714]
  38. Curr Pediatr Rep. 2022;10(1):11-17 [PMID: 35127274]
  39. Lancet Child Adolesc Health. 2022 Sep;6(9):614-623 [PMID: 35752194]
  40. Pediatr Neurol. 2022 Jul;132:1-3 [PMID: 35598584]
  41. PM R. 2022 Oct;14(10):1241-1269 [PMID: 36169159]
  42. Pediatrics. 2022 Sep 1;150(3): [PMID: 35765138]
  43. Lancet Child Adolesc Health. 2021 Mar;5(3):167-177 [PMID: 33338439]
  44. Eur J Pediatr. 2024 May;183(5):2375-2382 [PMID: 38446228]
  45. Sci Rep. 2022 Jun 23;12(1):9950 [PMID: 35739136]
  46. Pediatrics. 2022 Aug 1;150(2): [PMID: 35642018]
  47. Virol J. 2024 Jan 11;21(1):16 [PMID: 38212781]
  48. Future Microbiol. 2022 May;17(8):577-588 [PMID: 35360923]

Word Cloud

Created with Highcharts 10.0.0PASCCOVID-19USstudieschildrenadolescentssymptomsinfectionsequelaeclinicalepidemiologyUnitedreviewpediatric29PostacutePediatricsubsetexperiencerecurrentpersistentfollowingSARS-CoV-2knownpostacutehoweverwithinStatesyetwellunderstoodscopingaimssynthesizecomprehensiveliteraturesearchconducteddatabasesqueriedinceptionJanuary2024Studiesincluding<21yearsoldconsidered1028identifiedmetinclusioncriteriaPrevalencerangedless1%-27%RiskfactorsincludedolderagefemalesexasthmaobesitysevereinitialCommondyspneafatigueheadacheschestpainmultidisciplinaryapproachdiagnosismanagementcommonacrosshighriskbiaslimitedlackstandardizeddefinitionsshortfollow-updurationestablishesfoundationunderstandinghighlightscriticalneedcontinuedresearchoptimizepreventiontreatmentstrategiesSequelaePatientsWithinStates:ScopingReviewLongCOVID

Similar Articles

Cited By